TriPath Expanded Pap Labeling Data Claim Closes Gap With Cytyc
This article was originally published in The Gray Sheet
Executive Summary
TriPath expects narrower price differences between its SurePath and Cytyc's ThinPrep Pap test alternative over the long-term after receiving FDA sign-off on labeling that puts the tests on par for efficacy